Literature DB >> 7639467

Laryngeal dysplasia: epidemiology and treatment outcome.

K E Blackwell1, T C Calcaterra, Y S Fu.   

Abstract

A retrospective analysis was undertaken of 65 patients with long-term follow-up for laryngeal squamous dysplasia. Based on the degree of dysplasia demonstrated on initial biopsy, 0 of 6 patients showing hyperkeratosis without dysplasia, 3 of 26 patients (12%) showing mild dysplasia, 5 of 15 patients (33%) showing moderate dysplasia, 4 of 9 patients (44%) showing severe dysplasia, and 1 of 9 patients (11%) showing carcinoma in situ eventually progressed to invasive carcinoma. An analysis was made of the impact of various treatment modalities in 33 patients demonstrating moderate dysplasia, severe dysplasia, or carcinoma in situ. Invasive carcinoma developed in 10 of 21 patients (48%) treated endoscopically and 0 of 12 patients treated by more aggressive therapy, including external beam radiotherapy, partial laryngectomy, or total laryngectomy. Of the patients in the endoscopic therapy group who developed invasive carcinoma, all were salvaged successfully. The overall rate of laryngeal preservation was 15 of 21 patients (71%) in the endoscopic treatment group and 11 of 12 patients (92%) in the aggressive treatment group. This difference is not statistically significant. We conclude that there is a moderately high rate of progression to invasive carcinoma in patients undergoing repeated endoscopic therapy for intraepithelial neoplasms of the larynx. However, with close, long-term follow-up, patients undergoing endoscopic therapy have an overall outcome similar to that in patients treated with partial laryngectomy or radiotherapy prior to developing invasive disease.

Entities:  

Mesh:

Year:  1995        PMID: 7639467     DOI: 10.1177/000348949510400802

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  7 in total

1.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

2.  Vocal fold hyperplastic lesions: an evaluation of surgical outcome with videolaryngostroboscopy.

Authors:  Melek Kezban Gürbüz; Leman Birdane; Mustafa Fuat Açıkalın; Ertuğrul Colak; Erkan Ozüdoğru; Cemal Cingi; Armağan Incesulu
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

Review 3.  Oral premalignant lesions: from the pathological viewpoint.

Authors:  Toshiyuki Izumo
Journal:  Int J Clin Oncol       Date:  2011-01-14       Impact factor: 3.402

Review 4.  Management of laryngeal dysplasia: a review.

Authors:  Maziar Sadri; Jeremy McMahon; Andrew Parker
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-06       Impact factor: 2.503

5.  [Perceptual and automatic voice and speech analysis of chronic laryngitis and T1 vocal cord cancer].

Authors:  B Bartke; T Haderlein; M Döllinger; E Nöth; S Graf; U Eysholdt; A Ziethe
Journal:  HNO       Date:  2013-08       Impact factor: 1.284

6.  Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany.

Authors:  Karel Kostev; Louis E C Jacob; Matthias Kalder; Andreas M Sesterhenn; David Ulrich Seidel
Journal:  Mol Clin Oncol       Date:  2018-03-21

7.  Treatment with laser CO2 cordectomy and clinical implications in management of mild and moderate laryngeal precancerosis.

Authors:  A Minni; M Barbaro; G Rispoli; F Diaferia; D Bernardeschi; R Filipo
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-26       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.